(Q37111197)

18 August 2017

Reporting practices of pharmacodynamic studies involving invasive research procedures in cancer trials (English)

1 reference

18 August 2017

1 reference

G A Freeman

1

1 reference

18 August 2017

J Kimmelman

series ordinal

2

1 reference

18 August 2017

J Dancey

series ordinal

3

1 reference

18 August 2017

J G Monzon

series ordinal

4

1 reference

18 August 2017

language of work or name

English

0 references

publication date

25 July 2013

1 reference

British Journal of Cancer

18 August 2017

1 reference

18 August 2017

109

1 reference

18 August 2017

4

1 reference

18 August 2017

897-908

1 reference

The ethical use of mandatory research biopsies

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3749582

Biomarker studies: a call for a comprehensive biomarker study registry

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3749582

Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3749582

Performing nondiagnostic research biopsies in irradiated tissue: a review of scientific, clinical, and ethical considerations

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3749582

Quality of reporting of randomized controlled trials in general endocrinology literature

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3749582

Trends in the use and role of biomarkers in phase I oncology trials

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3749582

Almost all articles on cancer prognostic markers report statistically significant results

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3749582

Stereotactic large-core needle breast biopsy: analysis of pain and discomfort related to the biopsy procedure

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3749582

Pharmacodynamic biomarkers for molecular cancer therapeutics

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3749582

Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3749582

New science-based endpoints to accelerate oncology drug development

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3749582

Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3749582

Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3749582

How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3749582

Replication validity of genetic association studies

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3749582

Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3749582

Use of research biopsies in clinical trials: are risks and benefits adequately discussed?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3749582

Attitudes of patients with metastatic breast cancer toward research biopsies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3749582

Publication and reporting conduct for pharmacodynamic analyses of tumor tissue in early-phase oncology trials

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3749582

Quality of randomized controlled trials reporting in the treatment of sarcomas.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3749582

Performance of biopsies in clinical research.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3749582

Quality of randomized controlled trials reporting in the primary treatment of brain tumors

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3749582

REporting recommendations for tumour MARKer prognostic studies (REMARK).

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3749582

Reporting recommendations for tumor marker prognostic studies (REMARK).

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3749582

When are research risks reasonable in relation to anticipated benefits?

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3749582

Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3749582

A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy

3 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2013.417

Quality of Reporting of Randomized Trials as a Measure of Methodologic Quality

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2013.417

Analysis of consent validity for invasive, nondiagnostic research procedures

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3749582

Are we taking without giving in return? The ethics of research-related biopsies and the benefits of clinical trial participation

20 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3749582

Selective reporting biases in cancer prognostic factor studies

20 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23887602

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Biomarkers in phase I oncology trials: signal, noise, or expensive distraction?

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23887602

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Use of pharmacokinetic/pharmacodynamic biomarkers to support rational cancer drug development

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23887602

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/BJC.2013.417

1 reference

18 August 2017

1 reference

18 August 2017

PubMed publication ID

23887602

1 reference